抗毒素の世界市場レポート 2025年

抗毒素の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.4％で27億4,000万米ドルに成長します。予測期間の成長は、気候変動によるヘビの生息地への影響、ヘビが生息しやすい地域の人口増加、抗毒素製剤の進歩、世界的な健康安全保障への取り組み、抗毒素開発のための共同作業などに起因すると考えられます。予測期間における主な動向としては、データ分析の統合、教育とトレーニングの重視、生産規模拡大のための戦略的提携、規制枠組みの改善、新規治療標的の研究などが挙げられます。

ヘビによる咬傷の増加は、抗毒素市場を将来的に押し上げると予測されています。ヘビによる咬傷は、毒ヘビに咬まれた際の毒素により、死に至る可能性のある病気を引き起こす可能性のある傷害です。抗毒素は、適切な治療量を迅速に投与することで、ヘビ咬傷に伴う症状のほとんどを予防または緩和できる可能性のある特定の治療薬です。例えば、2023年9月、スイスに本部を置く公衆衛生を専門とする国連機関である世界保健機関（WHO）は、全世界で毎年約540万人がヘビに咬まれ、約180万～270万人の中毒患者が発生していると報告しました。ヘビに咬まれたために命を落とす人の数は、年間8万1,410人から13万7,880人と推定されています。このイニシアチブは、2030年までにヘビ咬傷による死亡率と障害を50％減少させることを目標としています。その結果、ヘビ咬傷の発生率の上昇が抗毒素市場の成長を促進しています。

研究開発活動の高まりが、今後の抗毒素市場の成長を促進すると予測されます。抗毒素分野の研究開発における継続的な努力は、より高度で効果的な製剤の発見と創造につながります。科学者や製薬会社は、抗毒素製品の有効性、安全性、特異性を向上させ、より良い治療結果を達成し、副作用を最小限に抑えることに注力しています。例えば、ルクセンブルクに本部を置く欧州連合（EU）の統計局であるユーロスタットは2023年12月、2022年のEUにおける研究開発費の66％を企業部門が占め、総額2,330億ユーロに上ると報告しました。次いで高等教育部門が22％（760億ユーロ）、政府部門が11％（370億ユーロ）、民間の非営利部門はわずか1％（50億ユーロ）でした。したがって、研究開発活動の活発化が抗毒素市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の抗毒素市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の抗毒素市場：成長率分析
• 世界の抗毒素市場の実績：規模と成長、2019～2024年
• 世界の抗毒素市場の予測：規模と成長、2024～2029年、2034年
• 世界の抗毒素総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗毒素市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 一価
• 多価
• その他
• 世界の抗毒素市場：動物別、実績と予測、2019～2024年、2024～2029年、2034年
• ヘビ
• サソリ
• クモ
• その他
• 世界の抗毒素市場：作用機序別、実績と予測、2019～2024年、2024～2029年、2034年
• 細胞毒性
• 神経毒性
• 血液毒性
• 心臓毒性
• 筋毒性
• その他
• 世界の抗毒素市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 外来手術センター
• その他
• 世界の抗毒素市場：一価のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ヘビの種類に応じた抗毒素
• 毒の種類に応じた抗毒素
• 世界の抗毒素市場：多価のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 広域スペクトル抗毒素
• 地域別多価抗毒素
• 世界の抗毒素市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• その他の毒に対する抗毒素
• 組み換え抗毒素
• 希少毒物に対する抗毒素

第7章 地域別・国別分析

• 世界の抗毒素市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の抗毒素市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗毒素市場：競合情勢
• 抗毒素市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Commonwealth Serum Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Incepta Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
  • Bharat Serums and Vaccines Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Rare Disease Therapeutics Inc.
• Vins Bioproducts Limited
• Boehringer Ingelheim International GmbH
• Boston Scientific Corporation
• Haffkine Bio-Pharmaceutical Corporation Limited
• MicroPharm Limited
• Latoxan SAS
• Serum Institute of India Pvt. Ltd.
• BSV Group
• Shanghai Serum Biotech Co Ltd.
• British Technology Group International
• South African Vaccine Producers
• Bioclon Institute
• Inosan Biopharma
• Instituto Bioclon S.A. de C.V.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗毒素市場2029年：新たな機会を提供する国
• 抗毒素市場2029年：新たな機会を提供するセグメント
• 抗毒素市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antivenom, also referred to as antivenin, is an antibody therapy designed to neutralize the toxins present in specific venoms when administered promptly after a bite. It is commonly employed in the treatment of poisonous animal bites or stings, such as those inflicted by rattlesnakes, moccasins, and copperheads.

The primary categories of antivenom include monovalent, polyvalent, and others. Monovalent antivenom is a specialized formulation crafted to counteract the effects of venom from a single species of snake or a specific toxin. These formulations are utilized to address venoms produced by a variety of animals, including snakes, scorpions, spiders, among others. They operate through diverse modes of action, such as cytotoxic, neurotoxic, hemotoxic, cardiotoxic, myotoxic, and others. These antivenom therapies are utilized by various end-users, including hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The antivenom market research report is one of a series of new reports from The Business Research Company that provides antivenom market statistics, including antivenom industry global market size, regional shares, competitors with a antivenom market share, detailed antivenom market segments, market trends and opportunities, and any further data you may need to thrive in the antivenom industry. This antivenom market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antivenom market size has grown strongly in recent years. It will grow from$1.92 billion in 2024 to $2.06 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to the high incidence of snakebites, geographic distribution of venomous snakes, limited access to medical facilities, agricultural and rural activities, and public health initiatives

The antivenom market size is expected to see strong growth in the next few years. It will grow to $2.74 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to climate change's impact on snake habitats, population growth in snake-prone regions, advancements in antivenom formulations, global health security initiatives, and collaborative efforts for antivenom development. Major trends in the forecast period include integration of data analytics, focus on education and training, strategic alliances for production scale-up, regulatory framework improvements, and research in novel therapeutic targets.

The increasing occurrence of snake bites is anticipated to boost the antivenom market in the future. Snake bites are injuries that can result in a potentially deadly disease due to toxins in the bite of a venomous snake. Antivenom is a specific treatment that, when administered promptly and at the correct therapeutic dosage, can potentially prevent or alleviate most of the symptoms associated with snakebite envenoming. For example, in September 2023, the World Health Organization (WHO), a United Nations agency based in Switzerland focused on public health, reported that around 5.4 million people are bitten by snakes globally each year, leading to approximately 1.8 to 2.7 million cases of envenoming. Annually, an estimated 81,410 to 137,880 individuals lose their lives due to snake bites. This initiative aims to achieve a 50% reduction in mortality and disability caused by snakebite envenoming by 2030. Consequently, the rising incidence of snake bites is propelling the growth of the antivenom market.

The rising research and development activities are anticipated to drive the growth of the antivenom market in the future. Continuous efforts in research and development within the antivenom field lead to the discovery and creation of more advanced and effective formulations. Scientists and pharmaceutical companies are focused on improving the efficacy, safety, and specificity of antivenom products to achieve better treatment outcomes and minimize side effects. For example, in December 2023, Eurostat, the statistical office of the European Union based in Luxembourg, reported that in 2022, the business enterprise sector accounted for 66% of research and development expenditure in the EU, totaling €233 billion. This was followed by the higher education sector at 22% (€76 billion), the government sector at 11% (€37 billion), and the private non-profit sector at just 1% (€5 billion). Therefore, the increasing research and development activities are fueling the growth of the antivenom market.

Leading companies in the antivenom market are working on advanced technologies, including public-benefit target products, to enhance the efficacy, safety, and accessibility of antivenoms, with the ultimate goal of improving patient outcomes and alleviating the global burden of snakebite envenomation. Public-benefit target products refer to healthcare innovations or medical products developed primarily to meet specific public health needs, especially in underserved or vulnerable populations. For example, in June 2023, Bharat Serums and Vaccines Ltd., a biopharmaceutical company based in the US, partnered with the Indian Institute of Science, a public institution in India, to develop region-specific antivenoms for snakebites in India. This collaboration aims to enhance treatment effectiveness and lessen the public health impact of snakebites in the affected areas.

Major enterprises within the antivenom market are forging strategic partnerships to foster innovation and fortify their market presence. An illustrative instance is the collaboration between Bharat Serums and Vaccines Limited, an India-based pharmaceutical company, and the Indian Institute of Science (IISc) Bengaluru, a public university in India. Their partnership, established in August 2022, endeavors to advance the development of antivenoms tailored to specific regions. The joint effort seeks to pioneer the next generation of snakebite therapy in India by addressing the complexities stemming from variations in venoms across snake species and within regions. Present treatments predominantly rely on a single polyvalent antivenom designed for the country's 'big four' snakes, revealing limitations in efficacy as indicated by recent research. The collaboration focuses on creating region-specific antivenoms to elevate the effectiveness of snakebite therapy and ultimately save lives.

In June 2024, MicroPharm Limited, a pharmaceutical company based in the UK, announced its acquisition of Sanofi Pasteur for an undisclosed sum. This acquisition is intended to enhance MicroPharm's portfolio of vaccine products and bolster its research and development capabilities. Sanofi Pasteur is a global pharmaceutical company located in France, specializing in the research, development, manufacturing, and distribution of vaccines and biological products, including antivenoms.

Major companies operating in the antivenom market include Pfizer Inc., Commonwealth Serum Laboratories, Merck KGaA, Incepta Pharmaceuticals Limited, Bharat Serums and Vaccines Limited, Rare Disease Therapeutics Inc., Vins Bioproducts Limited, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Haffkine Bio-Pharmaceutical Corporation Limited, MicroPharm Limited, Latoxan SAS, Serum Institute of India Pvt. Ltd., BSV Group, Shanghai Serum Biotech Co Ltd., British Technology Group International, South African Vaccine Producers, Bioclon Institute, Inosan Biopharma, Instituto Bioclon S.A. de C.V., F. Hoffmann-La Roche AG, Protherics Inc., Sanofi Pasteur SA, Venom Supplies Pty Ltd, Instituto Clodomiro Picado, Laboratorios Silanes S.A. de C.V., Instituto Biologico Argentino S.A., Instituto Vital Brazil, Instituto Butantan, Instituto Nacional de Produccion de Biologicos, Instituto de Biotecnologia de la UNAM

North America was the largest region in the global antivenom market size in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antivenom market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antivenom market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The antivenom market consists of sales of taipan antivenom and death adder antivenom. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antivenom Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antivenom market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antivenom ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antivenom market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Monovalent; Polyvalent; Other Types
• 2) By Animal: Snakes; Scorpions; Spiders; Other Animals
• 3) By Mode of Action: Cytotoxic; Neurotoxic; Hemotoxic; Cardiotoxic; Myotoxic; Other Modes Of Action
• 4) By End User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
• Subsegments:
• 1) By Monovalent: Specific Antivenoms For Individual Snake Species; Specific Antivenoms For Individual Venom Types
• 2) By Polyvalent: Broad-Spectrum Antivenoms; Regional Polyvalent Antivenoms
• 3) By Other Types: Antivenoms For Other Venoms; Recombinant Antivenoms; Antivenom For Rare Venoms
• Companies Mentioned: Pfizer Inc.; Commonwealth Serum Laboratories; Merck KGaA; Incepta Pharmaceuticals Limited; Bharat Serums and Vaccines Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antivenom Market Characteristics

3. Antivenom Market Trends And Strategies

4. Antivenom Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Antivenom Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antivenom PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antivenom Market Growth Rate Analysis
• 5.4. Global Antivenom Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antivenom Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antivenom Total Addressable Market (TAM)

6. Antivenom Market Segmentation

• 6.1. Global Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monovalent
• Polyvalent
• Other Types
• 6.2. Global Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Snakes
• Scorpions
• Spiders
• Other Animals
• 6.3. Global Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytotoxic
• Neurotoxic
• Hemotoxic
• Cardiotoxic
• Myotoxic
• Other Modes Of Action
• 6.4. Global Antivenom Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Other End-Users
• 6.5. Global Antivenom Market, Sub-Segmentation Of Monovalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Specific Antivenoms For Individual Snake Species
• Specific Antivenoms For Individual Venom Types
• 6.6. Global Antivenom Market, Sub-Segmentation Of Polyvalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Broad-Spectrum Antivenoms
• Regional Polyvalent Antivenoms
• 6.7. Global Antivenom Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antivenoms For Other Venoms
• Recombinant Antivenoms
• Antivenom For Rare Venoms

7. Antivenom Market Regional And Country Analysis

• 7.1. Global Antivenom Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antivenom Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antivenom Market

• 8.1. Asia-Pacific Antivenom Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antivenom Market

• 9.1. China Antivenom Market Overview
• 9.2. China Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antivenom Market

• 10.1. India Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antivenom Market

• 11.1. Japan Antivenom Market Overview
• 11.2. Japan Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antivenom Market

• 12.1. Australia Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antivenom Market

• 13.1. Indonesia Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antivenom Market

• 14.1. South Korea Antivenom Market Overview
• 14.2. South Korea Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antivenom Market

• 15.1. Western Europe Antivenom Market Overview
• 15.2. Western Europe Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antivenom Market

• 16.1. UK Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antivenom Market

• 17.1. Germany Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antivenom Market

• 18.1. France Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antivenom Market

• 19.1. Italy Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antivenom Market

• 20.1. Spain Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antivenom Market

• 21.1. Eastern Europe Antivenom Market Overview
• 21.2. Eastern Europe Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antivenom Market

• 22.1. Russia Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antivenom Market

• 23.1. North America Antivenom Market Overview
• 23.2. North America Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antivenom Market

• 24.1. USA Antivenom Market Overview
• 24.2. USA Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antivenom Market

• 25.1. Canada Antivenom Market Overview
• 25.2. Canada Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antivenom Market

• 26.1. South America Antivenom Market Overview
• 26.2. South America Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antivenom Market

• 27.1. Brazil Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antivenom Market

• 28.1. Middle East Antivenom Market Overview
• 28.2. Middle East Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antivenom Market

• 29.1. Africa Antivenom Market Overview
• 29.2. Africa Antivenom Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antivenom Market, Segmentation By Animal, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antivenom Market, Segmentation By Mode of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antivenom Market Competitive Landscape And Company Profiles

• 30.1. Antivenom Market Competitive Landscape
• 30.2. Antivenom Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Commonwealth Serum Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Incepta Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bharat Serums and Vaccines Limited Overview, Products and Services, Strategy and Financial Analysis

31. Antivenom Market Other Major And Innovative Companies

• 31.1. Rare Disease Therapeutics Inc.
• 31.2. Vins Bioproducts Limited
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Boston Scientific Corporation
• 31.5. Haffkine Bio-Pharmaceutical Corporation Limited
• 31.6. MicroPharm Limited
• 31.7. Latoxan SAS
• 31.8. Serum Institute of India Pvt. Ltd.
• 31.9. BSV Group
• 31.10. Shanghai Serum Biotech Co Ltd.
• 31.11. British Technology Group International
• 31.12. South African Vaccine Producers
• 31.13. Bioclon Institute
• 31.14. Inosan Biopharma
• 31.15. Instituto Bioclon S.A. de C.V.

32. Global Antivenom Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antivenom Market

34. Recent Developments In The Antivenom Market

35. Antivenom Market High Potential Countries, Segments and Strategies

• 35.1 Antivenom Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antivenom Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antivenom Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer